View Now | CP-RND: An Introduction to the Patient Community

Hosted by the C-Path team, you can view this recorded webinar to learn more about the Critical Path for Rare Neurodegenerative Diseases public-private partnership.

This webinar and patient-focused roundtable will deliver an enhanced understanding of:

  • The CP-RND strategic plan, its stakeholder groups and program deliverables
  • The envisioned impact of CP-RND on medical product development in rare neurodegenerative diseases
  • Perspectives from patients, regulators and the industry on the public-private partnership and the rare neurodegenerative disease community

Speakers and panelists included:

Ronald J. Bartek
Co-founder/President, Friedreich’s Ataxia Research Alliance
Lauren Boak, PhD
Lifecycle Leader, GPS NSRD, Roche
Michelle Campbell, PhD
Associate Director, Stakeholder Engagement and Clinical Outcomes, U.S. Food and Drug Administration
Jacqueline Corrigan-Curay, JD, MD
Principal Deputy Center Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Philip Green
ALS Patient Advocate
Collin Hovinga, PharmD, MS, FCCP
Vice President of the Rare and Orphan Disease Programs, Critical Path Institute
Walter Koroshetz, MD
Director, National Institute of Neurological Disorders and Stroke
Terina N. Martinez, PhD
Executive Director, Critical Path for Rare Neurodegenerative Diseases, Critical Path Institute
Klaus Romero, MD, MS, FCCP
Chief Science Officer; Executive Director of Clinical Pharmacology, Critical Path Institute
Celia Witten, MD, PhD
Deputy Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration